The drug could change the course of the AIDS epidemic. But the Trump administration has gutted the programs that might have paid for it in low-income countries.

The drug could change the course of the AIDS epidemic. But the Trump administration has gutted the programs that might have paid for it in low-income countries.

But the Trump administration’s cuts to HIV programs in the U.S. and abroad could undermine the drug’s rollout.